Fructose Worsens Liver Disease

32 + articles about liver health concerns can be found in Natural Health News

Our Liver cleansing and Liver care products have provided excellent results to hundreds of clients over the years...contact us for more information.

This is one indication of the need for detoxification. Colon cleansing IS NOT detoxification. Our decades of experience with detoxification products and programs offers much more to our clients than found elsewhere.

Cigarette smoking, fructose consumption exacerbates liver disease, study finds

ScienceDaily (2010-04-27) -- Recent studies suggest that modifiable risk factors such as cigarette smoking and fructose consumption can worsen nonalcoholic fatty liver disease (NAFLD). With NAFLD, fat accumulates in the liver of overweight individuals despite drinking little alcohol, causing in some cases liver scarring that can lead to liver failure. Identifying modifiable factors that contribute to disease severity and progression is essential in improving patient outcomes. ... > read full article

ARAVA and Liver Failure

Another fluoride-based drug cause serious problems.

Often, in mainstream medicine, the issue of wheat allergy is overlooked in RA (rheumatoid arthritis).

A general approach to RA is to use niacinamide, 250 mg, one tablet taken 4 times a day. 

FDA Adds Liver Failure Warning to RA Drug

By Cole Petrochko, Staff Writer, MedPage Today

WASHINGTON -- The FDA has expanded the black box warning to the label of the rheumatoid arthritis drug leflunomide (Arava) to include possible fatal liver damage.
The agency received 49 adverse event reports -- including instances of jaundice, coagulopathy, encephalopathy, and 14 fatalities -- about the drug from August 2002 to May 2009. Of the patients reporting adverse events, 36 were hospitalized.
Time before severe reactions occurred ranged from nine days to six years, with most experiencing an adverse event within the first six to 12 months of treatment.
The greatest risk occurred in patients taking other drugs that may cause liver damage while taking leflunomide and in patients with preexisting liver disease. These warnings have been included on the new label.
The label notes that liver enzymes should be monitored monthly for three months after the start of treatment. If ALT rises above two-times normal, treatment should be stopped and a cholestyramine washout should be administered to accelerate the removal of the drug from the body.
Patients with increased ALT should undergo liver function tests weekly until levels return to normal.
Patients who develop itching, yellow eyes or skin, dark urine, loss of appetite, or light-colored stool while taking leflunomide should contact a healthcare professional, the statement said.
The drug previously carried a boxed warning that the drug was contraindicated in pregnant women and women of childbearing age who do not use reliable contraception.